Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

Fig. 4

Proportion of patients achieving MCID in HAQ-DI, SGAP, and PGA through week 12/ET. MCID for HAQ-DI was defined as a decrease from baseline ≥0.22, SGAP as a decrease from baseline ≥10mm, and PGA as a decrease from baseline ≥10mm. All time points except for week 12/ET are observed data. At week 12/ET, last observation carried forward was used for missing scores. p values calculated using the chi-squared test (RAJ3) or Fisher’s exact test (RAJ4), with no adjustment made for multiplicity. *p<0.05; **p<0.01; ***p<0.001, peficitinib versus placebo. ET early termination, HAQ-DI Health Assessment Questionnaire – Disability Index, MCID minimal clinically important difference, PGA Physician’s Global Assessment of Arthritis, SGAP Subject’s Global Assessment of Pain

Back to article page